Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioVie Inc. stock logo
BIVI
BioVie
$8.19
+12.0%
$9.96
$6.20
$75.00
$15.23M0.73187,646 shs71,290 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.35
+3.2%
$0.36
$0.22
$4.79
$14.50M-0.281.09 million shs376,049 shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.75
+4.2%
$1.31
$0.73
$5.01
$29.61M1.722.34 million shs1.02 million shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$3.57
-2.2%
$3.29
$2.20
$5.27
$5.51M2.3428,526 shs9,798 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioVie Inc. stock logo
BIVI
BioVie
-18.69%+10.42%-29.03%-10.84%+89.62%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-1.45%+2.70%-10.79%-12.18%-83.62%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-6.67%+9.09%+37.70%+95.33%+143.90%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-0.27%-0.27%+26.74%+50.83%-12.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioVie Inc. stock logo
BIVI
BioVie
0.3837 of 5 stars
0.04.00.00.00.60.00.6
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
1.5388 of 5 stars
3.02.00.00.01.10.01.3
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
1.8592 of 5 stars
3.73.00.00.00.60.00.6
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
0.6343 of 5 stars
0.03.00.00.00.60.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioVie Inc. stock logo
BIVI
BioVie
4.00
Strong BuyN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.00
Hold$3.38864.29% Upside
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.33
Buy$14.00700.00% Upside
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$25.35 per shareN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.13 per shareN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$2.58M2.13N/AN/A$3.89 per share0.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioVie Inc. stock logo
BIVI
BioVie
-$32.12M-$79.10N/AN/AN/A-100.88%-78.49%8/21/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$3.96M-$2.38N/AN/AN/A-142.10%-57.31%-49.30%8/12/2025 (Estimated)

Latest XBIO, LPTX, BIVI, and MIRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.10N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$0.64N/AN/AN/A$0.48 millionN/A
8/11/2025Q2 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.29N/AN/AN/AN/AN/A
5/14/2025Q1 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.15-$0.11+$0.04-$0.11N/AN/A
5/13/2025Q1 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.38-$0.37+$0.01-$0.37N/AN/A
5/13/2025Q1 2025
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$0.72-$0.59+$0.13-$0.59$0.52 million$0.59 million
5/12/2025Q3 2025
BioVie Inc. stock logo
BIVI
BioVie
-$3.20-$1.50+$1.70-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioVie Inc. stock logo
BIVI
BioVie
N/A
9.31
9.31
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
2.41
2.41
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
12.86
12.86
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A
8.20
8.20

Institutional Ownership

CompanyInstitutional Ownership
BioVie Inc. stock logo
BIVI
BioVie
4.59%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
BioVie Inc. stock logo
BIVI
BioVie
2.39%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
7.50%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
6.65%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
14.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioVie Inc. stock logo
BIVI
BioVie
101.86 million1.82 millionNo Data
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
216.92 million15.80 millionNot Optionable
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
41.54 million1.32 millionNot Optionable

Recent News About These Companies

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioVie stock logo

BioVie NASDAQ:BIVI

$8.19 +0.88 (+12.04%)
Closing price 04:00 PM Eastern
Extended Trading
$7.86 -0.32 (-3.97%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.35 +0.01 (+3.24%)
Closing price 04:00 PM Eastern
Extended Trading
$0.35 0.00 (0.00%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.75 +0.07 (+4.17%)
Closing price 04:00 PM Eastern
Extended Trading
$1.76 +0.01 (+0.57%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Xenetic Biosciences stock logo

Xenetic Biosciences NASDAQ:XBIO

$3.57 -0.08 (-2.19%)
Closing price 04:00 PM Eastern
Extended Trading
$3.60 +0.03 (+0.70%)
As of 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.